Hjem › Leverkreft (hepatocellulært karcinom)
Kliniske studier for Leverkreft (hepatocellulært karcinom) rekrutterer i USA
131 studier for Leverkreft (hepatocellulært karcinom) rekrutterer deltakere på steder over hele USA.
Byer med flest studier
- Houston, TX31 studier
- New York City, NY24 studier
- Dallas, TX19 studier
- Los Angeles, CA19 studier
- Boston, MA18 studier
- Cleveland, OH18 studier
- Chicago, IL16 studier
- Philadelphia, PA16 studier
- Pittsburgh, PA15 studier
- San Francisco, CA14 studier
- Orange, CA14 studier
- Jacksonville, FL14 studier
- San Antonio, TX13 studier
- St. Louis, MO13 studier
- Rochester, MN12 studier
- Detroit, MI11 studier
- Portland, OR11 studier
- Baltimore, MD11 studier
- Atlanta, GA11 studier
- Seattle, WA10 studier
- Nashville, TN10 studier
- Mountain View, CA10 studier
- Washington, DC10 studier
- Arlington, VA9 studier
- Baldwin Park, CA9 studier
- Ann Arbor, MI9 studier
- Birmingham, AL8 studier
- Durham, NC8 studier
- Milwaukee, WI8 studier
- Santa Monica, CA8 studier
- San Diego, CA8 studier
- Scottsdale, AZ7 studier
- Phoenix, AZ7 studier
- Omaha, NE7 studier
- Miami, FL7 studier
- Tampa, FL7 studier
- Irvine, CA6 studier
- New Haven, CT6 studier
- Tucson, AZ6 studier
- Aurora, CO6 studier
Etter delstat
- Alabama9 studier
- Arizona17 studier
- California54 studier
- Colorado11 studier
- Connecticut8 studier
- Delaware3 studier
- District of Columbia4 studier
- Florida27 studier
- Georgia12 studier
- Hawaii3 studier
- Illinois20 studier
- Indiana5 studier
- Iowa3 studier
- Kentucky6 studier
- Louisiana5 studier
- Maryland16 studier
- Massachusetts19 studier
- Michigan20 studier
- Minnesota21 studier
- Missouri14 studier
- Nebraska8 studier
- Nevada4 studier
- New Hampshire3 studier
- New Jersey10 studier
- New York33 studier
- North Carolina11 studier
- Ohio23 studier
- Oklahoma5 studier
- Oregon11 studier
- Pennsylvania27 studier
- Rhode Island3 studier
- South Carolina6 studier
- Tennessee14 studier
- Texas50 studier
- Utah5 studier
- Virginia17 studier
- Washington15 studier
- Wisconsin12 studier
Nylig oppdaterte studier
Offisiell studietekst (engelsk)
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06995898A Study of ZW251 in Participants With Advanced Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT07164313Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT03942328Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06265285A Phase 1 Study of the Safety and Tolerability of CTX-10726
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07419841Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07285044Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06726161Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07227012National Liver Cancer Screening Trial
RekruttererFase 4
Alder 18 til 85 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06084234A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07291076Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT06915753Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
RekruttererFase 2
Alder 18 til 100 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07219459A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RekruttererFase 1
Alder 18 til 120 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06066138GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
RekruttererTidlig fase 1
Alder 18 til 99 · Alle kjønn · Oppdatert 18. sep. 2026 · NCT07627191A Study Evaluating a New Radiation Treatment Workflow (NGDS)
Rekrutterer
Alder 21 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07824583A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06427941Defining the Ablative Dose for Y-90 TARE
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT07586046A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06007846Evaluating Novel Therapies in ctDNA Positive GI Cancers
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05482516Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT04380545Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
RekruttererObservasjonsstudie
Alder 22 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06486454GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT04864054Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT06526338Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06811116Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.